The most important point with PAB is this
This isn't their drug PAT-SM6 failing to meet a Clinical trial tests as we see with so many bios
This is the company failing to produce the drug correctly for the trial
There is a very very big difference as it means what you are effectively talking about is a $1m extra cost and a time delay not that the actually drug is useless
Cash backed with big delays
Was apparently worth $45m in Oct Nov 2013 with trials expected in 18months-24minths but now isn't worth $5m with trials delayed and expected in 24months
Also I think it's pretty clear that the new CEO will bring in a new asset to diversify the company's focus while PATSM6 moves towards trials
Ann: Manufacturing Update - Clinical Trial Remains on Hold, page-50
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 915838 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1050244 | 4 |
View Market Depth
| Last trade - 16.12pm 21/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable